BACKGROUND & AIMS: Some women with inflammatory bowel disease require therapy with tumor necrosis factor (TNF) antagonists during pregnancy. It is not clear whether these drugs are transferred to the fetus via the placenta and then cleared, or whether structurally different TNF antagonists have different rates of transfer. METHODS: We studied 31 pregnant women with inflammatory bowel disease receiving infliximab (IFX, n = 11), adalimumab (ADA, n = 10), or certolizumab (CZP, n = 10). Serum concentrations of the drugs were measured at birth in the mother, infant, and in cord blood, and then monthly in the infant until the drugs were undetectable. Drug concentrations in the cord and the infant at birth were compared with those of the mother. RESULTS: Concentrations of IFX and ADA, but not CZP, were higher in infants at birth and their cords than in their mothers. The levels of CZP in infants and their cords were less than 2 μg/mL. The median level of IFX in the cord was 160% that of the mother, the median level of ADA in the cord was 153% that of the mother, and the median level of CZP in the cord was 3.9% that of the mother. IFX and ADA could be detected in the infants for as long as 6 months. No congenital anomalies or serious complications were reported. CONCLUSIONS: The TNF antagonists IFX and ADA are transferred across the placenta and can be detected in infants at birth; the drugs were detected in infants up to 6 months after birth. CZP has the lowest level of placental transfer, based on levels measured in cords and infants at birth, of the drugs tested.
BACKGROUND & AIMS: Some women with inflammatory bowel disease require therapy with tumor necrosis factor (TNF) antagonists during pregnancy. It is not clear whether these drugs are transferred to the fetus via the placenta and then cleared, or whether structurally different TNF antagonists have different rates of transfer. METHODS: We studied 31 pregnant women with inflammatory bowel disease receiving infliximab (IFX, n = 11), adalimumab (ADA, n = 10), or certolizumab (CZP, n = 10). Serum concentrations of the drugs were measured at birth in the mother, infant, and in cord blood, and then monthly in the infant until the drugs were undetectable. Drug concentrations in the cord and the infant at birth were compared with those of the mother. RESULTS: Concentrations of IFX and ADA, but not CZP, were higher in infants at birth and their cords than in their mothers. The levels of CZP in infants and their cords were less than 2 μg/mL. The median level of IFX in the cord was 160% that of the mother, the median level of ADA in the cord was 153% that of the mother, and the median level of CZP in the cord was 3.9% that of the mother. IFX and ADA could be detected in the infants for as long as 6 months. No congenital anomalies or serious complications were reported. CONCLUSIONS: The TNF antagonists IFX and ADA are transferred across the placenta and can be detected in infants at birth; the drugs were detected in infants up to 6 months after birth. CZP has the lowest level of placental transfer, based on levels measured in cords and infants at birth, of the drugs tested.
Authors: Fabian Schnitzler; Herma Fidder; Marc Ferrante; Vera Ballet; Maja Noman; Gert Van Assche; Bernard Spitz; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2011-01-06 Impact factor: 5.325
Authors: Geert R D'Haens; Remo Panaccione; Peter D R Higgins; Severine Vermeire; Miquel Gassull; Yehuda Chowers; Stephen B Hanauer; Hans Herfarth; Daan W Hommes; Michael Kamm; Robert Löfberg; A Quary; Bruce Sands; A Sood; G Watermeyer; G Watermayer; Bret Lashner; Marc Lémann; Scott Plevy; Walter Reinisch; Stefan Schreiber; Corey Siegel; Stephen Targan; M Watanabe; Brian Feagan; William J Sandborn; Jean Frédéric Colombel; Simon Travis Journal: Am J Gastroenterol Date: 2010-11-02 Impact factor: 10.864
Authors: Carla Arpino; Eliana Compagnone; Maria L Montanaro; Denise Cacciatore; Angela De Luca; Angelica Cerulli; Stefano Di Girolamo; Paolo Curatolo Journal: Childs Nerv Syst Date: 2010-03-27 Impact factor: 1.475
Authors: Z Zelinkova; C de Haar; L de Ridder; M J Pierik; E J Kuipers; M P Peppelenbosch; C J van der Woude Journal: Aliment Pharmacol Ther Date: 2011-03-01 Impact factor: 8.171
Authors: Uma Mahadevan; Salvatore Cucchiara; Jeffrey S Hyams; Flavio Steinwurz; F Nuti; Simon P L Travis; William J Sandborn; Jean-Frederio Colombel Journal: Am J Gastroenterol Date: 2010-12-14 Impact factor: 10.864
Authors: Charles W Randall; John A Vizuete; Nicholas Martinez; John J Alvarez; Karthik V Garapati; Mazyar Malakouti; Carlo M Taboada Journal: Therap Adv Gastroenterol Date: 2015-05 Impact factor: 4.409
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Claudia Lazarides; Elissa S Epel; Jue Lin; Elizabeth H Blackburn; Manuel C Voelkle; Claudia Buss; Hyagriv N Simhan; Pathik D Wadhwa; Sonja Entringer Journal: Brain Behav Immun Date: 2019-04-08 Impact factor: 7.217